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Abstract
Obsessive-compulsive disorder (OCD) is a disabling, mostly chronic, psychiatric condition with signiﬁcant
social and economic impairments and is a major public health issue. However, numerous patients are resistant
to currently available pharmacological and psychological interventions. Given that recent animal studies and
magnetic resonance spectroscopy research points to glutamate dysfunction in OCD, we investigated the metabo-
tropic glutamate receptor 5 (mGluR5) in patients with OCD and healthy controls. We determined mGluR5
distribution volume ratio (DVR) in the brain of ten patients with OCD and ten healthy controls by using
[11C]ABP688 positron-emission tomography. As a clinical measure of OCD severity, the Yale-Brown
Obsessive Compulsive Scale (Y-BOCS) was employed. We found no signiﬁcant global difference in mGluR5
DVR between patients with OCD and healthy controls. We did, however, observe signiﬁcant positive correla-
tions between the Y-BOCS obsession sub-score and mGluR5 DVR in the cortico-striatal-thalamo-cortical
brain circuit, including regions of the amygdala, anterior cingulate cortex, and medial orbitofrontal cortex
(Spearman’s ρ’s5=0.68, p<0.05). These results suggest that obsessions in particular might have an underlying
glutamatergic pathology related to mGluR5. The research indicates that the development of metabotropic
glutamate agents would be useful as a new treatment for OCD.
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Introduction
Individuals suffering from obsessive-compulsive
disorder (OCD) display recurrent, intrusive thoughts
(obsessions) and/or repetitive behaviour that the individ-
ual feels driven to perform (compulsions) (Hasler et al.,
2005, 2007). Patients recognize that these thoughts and
behaviours are excessive and unreasonable, and attempt
to suppress them. The obsessions and compulsions
cause signiﬁcant impairment in social and occupational
functioning (Fontenelle and Hasler, 2007), leading to
health cost burdens and personal patient tragedies.
According to the World Health Organization, OCD is
among the ten most disabling medical conditions
(Murray and Lopez, 1996) with a life-time prevalence
rate of 1.9–2.5% (Stein et al., 2000; Nestadt et al., 2010).
Advances in the pharmacological treatment of
OCD have increased since the 1980s, when seroton-
in reuptake inhibitors (SRI) were introduced as an inter-
vention method, successfully reducing the symptoms of
OCD in some patients (Hoehn-Saric et al., 2000). The suc-
cess rate of SRI treatments for OCD, even when combined
with psychological therapies such as cognitive beha-
vioural therapy, was only 40–60% (Nestadt et al.,
2010). Recently, research interest has shifted toward
examining the role of glutamate in OCD (Bhattacharyya
and Chakraborty, 2007; Riaza Bermudo-Soriano et al.,
2012; Wu et al., 2012). Magnetic resonance spectroscopy
(MRS) imaging studies have found reduced glutamate
concentrations in portions of the cortico-striatal-thalamo-
cortical brain circuit, such as the amygdala and orbito-
frontal cortex, in adults and children with OCD
(Bhattacharyya and Chakraborty, 2007). In a recent re-
view (Brennan et al., 2012) compared the results of 14
MRS studies investigating a glutamate-related chemical
in patients with OCD and healthy controls. The authors
reported that a majority of studies found decreased gluta-
mate metabolites in the anterior cingulate cortex (ACC) of
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adults and increased metabolites in the caudate
nucleus of children. Further evidence for the prominent
role of glutamate in OCD comes from preclinical studies
of pharmaceuticals that act on metabotropic glutamate
mGluR5 receptors. These antagonists have consistently
been reported to have anxiolytic effects in animal experi-
ments, and more speciﬁc effects on OCD-like behaviour
in animal models (Pittenger et al., 2006; Bhattacharyya
and Chakraborty, 2007; Riaza Bermudo-Soriano et al.,
2012). In addition, there are recent reports demonstrating
efﬁcacy of mGluR5 antagonists in preclinical tests related
to OCD (Spooren et al., 2000; Mehta et al., 2011).
Using positron emission tomography (PET) with the
successfully developed radiolabeled mGluR5 antagonist
([11C]ABP688) (Ametamey et al., 2007), which binds
with high selectivity to an allosteric site, we could
measure mGluR5 availability in healthy subjects and
patients with OCD. On the basis of previous theories
suggesting the involvement of the cortico-striatal-
thalamo-cortical brain circuit glutamate concentration in
OCD (Saxena et al., 1998; Wu et al., 2012), we predicted
changes in mGluR5 distribution volume ratio within
regions of interest (ROIs) that are part of this brain circuit,
such as the orbitofrontal cortex, ACC and subcortical
regions such as the amygdala.
Method
Subjects
Participants were recruited via local newspaper advertise-
ments and posters at Zurich University hospital, and
were assessed during a screening visit to the outpatient
psychiatry clinic of Zurich University hospital. Inclusion
criterion for the group of patients with OCD was the pres-
ence of obsessions and compulsions for at least 1 h every
day. To exclude individuals with additional current psy-
chiatric illnesses, all subjects were assessed with an
unstructured clinical interview by a psychiatrist, and the
Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
Text Revision (First et al., 2001). The clinical evaluation
also included a physical examination, laboratory tests,
and in some cases electrocardiography to ensure that
patients were eligible for the PET scan. Clinical measures
included the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS) (Goodman et al., 1989), Beck Anxiety
Inventory (BAI) (Beck et al., 1988) and the Beck
Depression Inventory (BDI) (Beck et al., 1961).
Exclusion criteria included additional current psychi-
atric, neurological, or medical disorders, pregnancy,
breastfeeding, history of psychosis, manic episodes,
substance dependence, nicotine consumption and autism.
Healthy controls were excluded if any current Axis I
mental illness or any counter-indication for PET scan
was determined. Magnetic resonance imaging was per-
formed on each subject and assessed by a radiologist to
exclude any structural brain pathology.
Subjects were enrolled in the study after they received
a full explanation of the study purpose and procedures,
and after written consent was obtained as approved by
the local ethics committee (Kantonale Ethikkommission
Zurich).
Positron emission tomography
A bolus/infusion protocol (Carson et al., 1993) that we pre-
viously evaluated for PET with [11C]ABP688 (Burger
et al., 2010) was applied. This protocol allows reliable
measurement of the relative distribution volume and re-
duction of potential bias due to arterial blood sampling
needed for absolute quantiﬁcation. Studies have demon-
strated that equilibrium between the tracer in tissue
and blood is achieved 40min after the start of radioligand
infusion (Burger et al., 2010). Each patient’s dynamic up-
take curve was checked for suitability. Catheters were
placed in the right antecubital vein for tracer injection
prior to scanning. Subjects were scanned using [11C]
ABP688 and a whole-body PET (Discovery VCT; GE
Healthcare, US) in three-dimensional mode with an axial
ﬁeld of view of 14.6 cm and an in-plane resolution of 7.0
mm. For attenuation correction, low-dose computed tom-
ography was acquired before tracer injection. A total of
600–800MBq of [11C]ABP688 in a 50ml volumewas admi-
nistered using an infusion pump (half was given as a bolus
over 2min and the other half was infused over the next
58min). Image acquisition and reconstruction was per-
formed as described earlier (Treyer et al., 2007). In brief,
the emission scan, which consisted of 20 frames (10 frames
of 60 s followed by 10 frames of 300 s, leading to a total
duration of 60min per acquisition), was initiated at the
start of the bolus injection. Transaxial images were recon-
structed to a 128×128 matrix with 35 slices of 2.34×2.34×
3.27 mm voxel size using ﬁltered back-projection. To de-
termine that equilibrium was reached in each subject, we
analysed the tissue time-activity curve in a cingular
(high receptor density) and a grey matter cerebellar (low
receptor density) region. We found that the activity
reached equilibrium at 30min. As the measure of receptor
availability, the ratio of tissue activity divided by the
cerebellar activity at equilibrium (CT/Ccer at 45–60min)
was chosen. At equilibrium, CT/Ccer is equal to the ratio
of the distribution volumes of the tracer in target and
reference tissue, (CT/Ccer)eq=VT/VND, where VND is the
distribution volume of the non-displaceable compartment
(Treyer et al., 2007)— in our case, the cerebellum. VT/VND
is referred to as the distribution volume ratio (DVR). It can
be further demonstrated that the DVR equals BPND+1,
where BPND is the binding potential in the target tissue,
which is often used as measure for receptor density div-
ided by afﬁnity (Innis et al., 2007).
Statistical analysis
Analyses were conducted using PMOD (Version 3.0;
PMOD Technologies, Switzerland, www.pmod.com).
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First, DVR images were transformed to a common space,
the Montreal Neurological Institute template. Pre-deﬁned
grey matter ROIs were applied to the normalized DVR
PET images. The ROIs included 24 regions: 4 cortical
(frontal, parietal, temporal, and occipital), 2 regions with-
in the cingulate gyrus (anterior and posterior), 3 regions
in the prosencephalon (caudate, putamen, and thalamus)
and 3 regions in the limbic system (medial orbitofrontal
cortex, amygdala, and medial temporal lobe). Addition-
ally, we calculated the average grey matter mGluR5
DVR using a grey matter mask with a pixel value cut-off
of 12. Two-sample two-tailed t-tests were used to test the
differences in mGluR5 DVR between the groups with
and without Bonferroni correction. Spearman correlations
were used to assess associations between continuous vari-
ables and mGluR5 DVR within each group.
Results
The clinical characteristics of ten OCD and ten age- and
gender-matched healthy subjects are shown in Table 1.
Age did not differ across the groups (t18=0.08, p=0.94),
and there was no signiﬁcant age difference between
male and female subjects in the total sample (t18=−0.61,
p=0.55). Additionally, we observed no difference in high-
est educational qualiﬁcation between the groups (all p’s>
0.20). Both groups differed with respect to the BDI (t18=
4.79, p<0.001) and BAI scores (t18=6.48, p<0.001) (See
Table 1). Seven patients with OCD had a history, but no
present episode, of major depressive disorder (MDD)
and two had a history of social phobia. Among the con-
trols, two individuals had a past major depressive epi-
sode. The mean [11C]ABP688 activity administered did
not differ signiﬁcantly between OCD and healthy subjects
(729±71 and 740±34MBq). Overall, we observed no sign-
iﬁcant difference in mGluR5 DVR between OCD and
healthy subjects in any ROI examined, with and without
correction for multiple tests. Figure 1 shows the distri-
bution of all DVRs over all regions in both groups reveal-
ing high overlap between groups. However, among
patients with OCD, Y-BOCS total score and mGluR5
DVR were positively correlated in the right medial tem-
poral (ρ=0.78, p=0.01), right medial orbitofrontal cortex
(ρ=0.83, p=0.03) and right parietal cortex (ρ=0.66, p=
0.04), as well as in the temporal lobes (right: ρ=0.87, p=
0.01; left: ρ=0.87, p=0.01). Interestingly, the YBOCS com-
pulsions sub-score did not correlate with mGluR5 DVR in
any ROI. However, the YBOCS obsession sub-score corre-
lated positively with the average grey matter mGluR5
DVR (ρ=0.72, p=0.02 (0.48 Bonf)). Speciﬁcally, the ob-
session sub-score correlated with mGluR5 in the ACC
(ρ=0.68, p=0.03 (0.72 Bonf)), right amygdala (ρ=0.74,
Table 1. Clinical characteristics of the two groups
Clinical characteristic OCD (n=10) Healthy subjects (n=10)
Gender (f/m) 9/1 7/3
Age (yr) 36.40 (8.59) 36.10 (8.06)
Duration of illness (yr) 11.60 (6.96) –
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Y-BOCS-Total score 26.00 (5.35)
Y-BOCS-Obsessions score 13.00 (2.94)
Y-BOCS-Compulsions score 13.10 (3.07)
OCD symptom clusters* Contamination/cleaning n=5 –
Harm/checking n=3
Symmetry/ordering n=5
Hoarding n=0
Miscellaneous n=8
Beck Depression Inventory score 9.70 (4.57) 2.10 (2.08)
Beck Anxiety Inventory score 14.40 (6.15) 1.60 (1.08)
Past psychiatric history* Major depressive disorder n=7 Major depression episode n=2
Social phobia n=4
Medication at time of study* Escitalopram n=1 –
Paroxetine n=1
Sertraline n=1
Fluctine n=1
Clomipramine with an adjunct Risperidone n=1
Highest educational qualiﬁcation* High school completed n=4 High school completed n=2
College completed n=6 College completed n=7
University completed n=0 University completed n=1
The data presented are Mean (S.D.), unless indicated otherwise.
* n refers to the number of participants within this category.
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p=0.02 (0.48 Bonf)), right frontal lobe (ρ=0.79, p=0.01
(0.245 Bonf)), medial temporal lobes (right: ρ=0.78, p=
0.01 (0.245 Bonf); left: ρ=0.77, p=0.01 (0.245 Bonf)),
medial orbitofrontal cortex (right: ρ=0.73, p=0.02 (0.48
Bonf); left: ρ=0.75, p=0.01 (0.245 Bonf)), parietal lobes
(right: ρ=0.80, p=0.01 (0.245 Bonf); left: ρ=0.82, p=0.01
(0.245 Bonf)), and temporal lobes (right: ρ=0.88, p<0.01
(0.245 Bonf); left: ρ=0.85, p=0.02 (0.48 Bonf)). Results
were the same when correlations were determined
with Pearson correlation. Figure 2a, b displays the correla-
tions between and Y-BOCS total score and mGluR5
DVR in right medial temporal cortex and right medial
orbitofrontal cortex (a) and Y-BOCS obsessions score
and mGluR5 DVR in ACC and right amygdala (b).
Figure 1 in the supplemental material shows that medi-
cation did not seem to have an effect on these correlations
in this study. Comparing the slopes of the regressions
with and without medication did also not reveal a signiﬁ-
cant difference (t=0.5, df=6). Controlling the correlation
for medication the correlation is 0.716 with 2-tailed
p=0.03, which is not much different from the result with-
out controlling for medication: ρ=0.74, p=0.02. To display
raw data variability Fig. 3a, b displays the values of
grey matter and ACC in controls, OCD with and without
medication. Figure 4 depicts mGluR5 DVR in OCD
patients with and without obsessions.
In the healthy control group, BDI and BAI scores
did not correlate with the mGluR5 DVR in any ROI.
However, in the OCD group, the BAI score was positively
correlated with the mGluR5 DVR in the right putamen
(ρ=0.68, p=0.03 (0.245 Bonf)) and the BDI score was posi-
tively correlated with mGluR5 DVR in the right caudate
(ρ=0.71, p=0.02 (0.245 Bonf)).
Discussion
In this PET study we investigated mGluR5 distribution
volume ratio of ten adult patients with OCD compared
2.20
Right medial
temporal cortex
Right medial
orbitofrontal cortex
Linear (right medial
temporal cortex)
Linear (right medial
orbitofrontal cortex)
ACC
Right amygdala
Linear (ACC)
Linear (right 
amygdala)
2.00
1.80
1.60
1.40
1.20
1.00
10 20
Y-BOCS Total score
30 40
m
G
lu
R
5 
D
V
R
2.20
2.40
2.60
2.00
1.80
1.60
1.40
1.20
1.00
5 10
Y-BOCS Obsessions score
15 20
m
G
lu
R
5 
D
V
R
(a)
(b)
Fig. 2. (a) Correlation between Y-BOCS obsessions score and
mGluR5 DVR in right medial temporal cortex and right medial
orbitofrontal cortex. (b) Correlation between Y-BOCS obsessions
score and mGluR5 DVR in ACC and amygdala.
Group
Control
2.50
2.00
1.50
A
ll 
re
gi
on
s
A
ll 
re
gi
on
s
1.00
0.50
2.50
2.00
1.50
1.00
0.50
20.0 15.0 10.0
Frequency Frequency
5.0 0.0 5.0 10.0 15.0 20.0
OCD
Fig. 1. Histogram of DVR in all regions over all subjects
comparing both groups showing high overlap.
Grey matter
2.0
1.8
1.6
D
V
R
 m
G
lu
R
5
1.4
1.2
1.0
Control Without 
medication
With 
medication
ACC
2.0
2.2
2.4
2.6
1.8
1.6
D
V
R
 m
G
lu
R
5
1.4
1.2
1.0
Control Without 
medication
With 
medication
(a)
(b)
Fig. 3. (a) Scattergrams of mGluR5 binding of grey matter.
Control, without medication and with medication group. (b)
Scatter grams of mGluR5 binding of ACC. Control, without
medication and with medication group.
4 F. Akkus et al.
to ten healthy controls. We did not ﬁnd global differences
between the two groups; however, we found signiﬁcant
positive correlations between the Y-BOCS obsession sub-
score and the mGluR5 DVR in the ACC, right amygdala,
right frontal cortex, grey matter, bilateral medial temporal
cortex, bilateral medial orbitofrontal cortex, bilateral par-
ietal lobe, left temporal lobe and right temporal lobe. The
compulsions score was not correlated with mGluR5 DVR
in any ROI.
Several factors may have contributed to the lack
of signiﬁcant differences in mGluR5 DVR between
patients with OCD and controls. OCD patients had a
higher load of depressive symptoms than control subjects.
Given that depression has been related to global reduc-
tions in mGluR5 binding (Deschwanden et al., 2011b),
this depression-related reduction might have counter-
balanced the potential obsessive symptoms related in-
crease in mGluR5 DVR, as seen within the OCD sample.
The correlation between mGluR5 DVR and the
obsession sub-score conﬁrms previous research using
different methodologies, such as MRS or animal
models, suggesting that glutamate plays an important
role in the pathogenesis of OCD (Pittenger et al., 2006;
Bhattacharyya and Chakraborty, 2007; Harvey and
Shahid, 2012; Riaza Bermudo-Soriano et al., 2012). Further-
more, we found that the obsession score correlated
with mGluR5 DVR in cortico-striatal-thalamo-cortical
brain circuit, including regions of the amygdala, ACC
and medial orbitofrontal cortex, conﬁrming the role of
this speciﬁc brain circuitry in OCD pathology. Indeed,
we found changes in mGluR5 distribution volume ratio
in key regions that were previously associated with
abnormalities in OCD (Rosenberg and Keshavan, 1998;
Szeszko et al., 2008). Using neuroimaging methods in
patients with OCD and healthy controls, structural
brain abnormalities have consistently been reported in
those regions that we also determined to be signiﬁcantly
affected, such as the amygdala (Rosenberg and Keshavan,
1998), ACC (Szeszko et al., 2008) and orbitofrontal cortex
(Rosenberg and Keshavan, 1998; Szeszko et al., 2008;
van den Heuvel et al., 2009). This suggests that structural
changes in brain anatomy might be associated with
molecular changes in glutamate function and receptor dis-
tribution. Additionally, frontal deﬁcits might be associated
with deﬁcits in executive function mechanisms (such as
obtrusive thinking) involved in obsessions, while glutama-
tergic changes in limbic regions might be associated with
fear/stress responses, which are commonly connected to
obsessions.
We found correlations between mGluR5 distribution
volume ratio and the obsessions, but not the compulsions
sub-score (or overall), which might suggest that each
has a distinguishable underlying pathophysiology.
Obsessions involving stress, conﬂict and executive func-
tion problems can be associated with glutamatergic
changes in key regions mediating such responses (i.e.
the amygdala, ACC and orbitofrontal cortex (Rosenberg
and Keshavan, 1998; Szeszko et al., 2008; van den
Heuvel et al., 2009)), whereas compulsions might have
a stronger motor component, potentially associated with
changes in the cerebellum, that have very low mGluR5
binding.
Several studies (DeLorenzo et al., 2011; Sandiego
et al., 2013; Wyckhuys et al., 2013) addressed the varia-
bility of [11C]ABP688 binding. With regards to intra-
subject variability’s test and re-test studies have not
shown signiﬁcant effects, except one study, which had
revealed an unexplained effect (Sandiego et al., 2013).
The question of present PET study was to explore if
there is a difference in metabotropic glutamate receptor
5 binding between healthy group and patients with
OCD and we did not ﬁnd a clear effect. Considering
potential medication targeting directly or indirectly the
mGluR5 system a further study analysing effects using
this tracer would nevertheless make sense but would
need a higher number of subjects to be enrolled to ensure
better power for detecting intra-individual changes.
One limitation of the current research is the relatively
small sample size. However, we recently determined
reduced mGluR5 receptor density in smokers and de-
pressed individuals by using a marginally larger number
of participants (Deschwanden et al., 2011b; Akkus et al.,
2013). Importantly, in the current BDI estimate only
three patients had a score over eleven. Nevertheless, the
effect of comorbidity was too small to ﬁnd a difference
0.0 2.3
0.0 2.3
0.0 2.3
Fig. 4. mGluR5 DVR in OCD patients with and without
obsessions. Figure depicts mGluR5 DVR in horizontal slices.
Upper row: average mGluR5 binding in the 11 subjects with
OCD. Middle and lower rows: subjects with OCD were
divided by median split; middle row shows the 4 subjects with
OCD with high Y-BOCS obsession scores (13–18), bottom row
shows the 6 subjects with OCD with low Y-BOCS obsession
scores (9–12).
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in tracer uptake between both groups. For test purposes
we used BDI as covariate comparing the grey matter up-
take between groups and did not ﬁnd an interesting
effect in any direction (univariate ANOVA without BDI:
F=0.914, p=0.352, with BDI as covariate: corrected
model F=1.78, p=0.199, for group effect F=3.46, p=0.08,
with BAI as covariate: corrected model F=1.164, p=
0.336, for group effect F=2.302 p=0.148).
A further limitation might be that some study patients
took medications for OCD symptoms (n=5), which could
have interfered with the results. This limitation may have
increased the probability of type II errors with respect to
differences between cases and controls. Since we did not
ﬁnd global changes in glutamate receptor density but
found very speciﬁc ROI changes in our OCD sample
that were correlated with obsessions but not compulsions,
it is very unlikely that this speciﬁc ﬁnding could be attrib-
uted to medications as they would more likely produce
non-speciﬁc global changes. Indeed, medication did not
seem to have an effect on the correlations in this study
(see Fig. 1 supplemental material). Also looking at data
distribution between the different groups (control, OCD
with and without medication) there seems no trend in
the data visible potentially related to medication (see
Fig. 3a, b). Finally, since some patients also reported
having been diagnosed with depression in the past, one
might suggest a potential confound here. However, we
carefully selected patients who were currently free of
any condition other than OCD. Additionally, in a recent
study we found that depression was associated with a de-
crease rather than an increase in mGluR5 receptor density
(Deschwanden et al., 2011b). Excluding the two control
subjects with a past major depressive episode did not
change the results of this study. Taken together, limita-
tions of this research might be the relative small sample
size and the comorbidity of some patients, therefore
further research, for instance using a large sample of
OCD patients receiving mGluR5-based treatment in a
controlled clinical trial, would be helpful to conﬁrm this
initial ﬁnding.
We used a bolus-infusion technique and normalized
the PET images to the cerebellar radioactivity concen-
tration to avoid the need for potentially painful arterial
cannulation. This reference tissue method was based on
previous in vivo and in vitro evidence demonstrating
that mGluR5 levels are extremely low in the cerebellum
relative to the predeﬁned ROIs in other brain areas
(Elmenhorst et al., 2010). A recent study demonstrated
that quantiﬁcation of mGluR5 receptor with [18F]FPEB
using non-invasive modelling with the cerebellum as a
reference region may be feasible (Barret et al., 2010). In
support of this, recent in vitro and in vivo studies sug-
gested negligible ABP688 binding in the cerebellum,
and validated the use of the cerebellum as a reference
region (Ametamey et al., 2007; Elmenhorst et al., 2010).
In addition, in a recent post-mortem study, mGluR5
protein expression was not observed in the cerebellum
(Deschwanden et al., 2011a). Previous studies on cerebel-
lar mRNA expression have demonstrated both the pres-
ence (Malherbe et al., 2002) and absence (Daggett et al.,
1995) of mGluR5 mRNA, or weak mRNA expression ex-
clusively in Bergmann glia (Berthele et al., 1999). In sum-
mary, in all studies of cerebellar mGluR5 concentration
that collected data from more than one subject (Patel
et al., 2007) found negligible mGluR5 expression in the
cerebellum, suggesting that the cerebellum can be used
as a reference region.
Overall, our research suggests that glutamatergic
transmission in cortico-striatal-thalamo-cortical brain cir-
cuits is related to obsessions—but not compulsions—in
OCD. Recent pharmacological studies and preclinical
animal studies have demonstrated promising anxiolytic
effects of some glutamate-based antagonists (Pittenger
et al., 2006; Harvey and Shahid, 2012; Riaza Bermudo-
Soriano et al., 2012). Speciﬁcally, it has been suggested
that compared to drugs acting on ionotropic glutamate
receptors, antagonists acting on metabotropic glutamate
receptors, such as the mGluR5, might be more speciﬁc
and cause less unwanted effects than ionotropic agents
(Pittenger et al., 2006; Harvey and Shahid, 2012; Riaza
Bermudo-Soriano et al., 2012). Our research identiﬁes
that the development of metabotropic glutamate-based
antagonists for OCD could offer a new treatment option
for patients with OCD.
Supplementary material
For supplementary material accompanying this paper,
visit http://dx.doi.org/10.1017/S1461145714000716.
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